Table 1 Baseline patient characteristics
|  | Primary efficacy population (n = 187) | Safety population (N = 199) |
|---|---|---|
Median age, years (range) | 60 (35–81) | 59 (35–81) |
Age distribution, n (%) | ||
  ≤65 years | 133 (71.1) | 142 (71.4) |
  >65 years | 54 (28.9) | 57 (28.6) |
Male, n (%) | 116 (62.0) | 125 (62.8) |
Durie-Salmon baseline MM stage, n (%) | ||
  I | 9 (4.8) | 9 (4.5) |
  II | 18 (9.6) | 19 (9.6) |
  III | 160 (85.6) | 171 (85.9) |
ECOG Performance Status score, n (%) | ||
  0 | 69 (36.9) | 73 (36.7) |
  1 | 92 (49.2) | 99 (49.7) |
  2 | 26 (13.9) | 27 (13.6) |
Renal function (creatinine clearance), n (%) | ||
  Normal (≥60 ml/min) | 125 (66.8) | 131 (65.8) |
  Mild-to-moderate impairment (≥30 to <60 ml/min) | 50 (26.7) | 54 (27.1) |
  Severe impairment (<30 ml/min) | 12 (6.4) | 14 (7.0) |
Median number of prior antimyeloma therapies, n (range) | 4 (1–15) | 4 (1–15) |
Number of prior antimyeloma therapies, n (%) | ||
  1–3 | 81 (43.3) | 86 (43.2) |
  4–6 | 64 (34.2) | 68 (34.2) |
  7–9 | 29 (15.5) | 32 (16.1) |
  10–15 | 13 (7.0) | 13 (6.5) |
Prior use of thalidomide or bortezomib, n (%) | ||
  Thalidomide | 130 (69.5) | 137 (68.8) |
  Bortezomib | 118 (63.1) | 127 (63.8) |
  Thalidomide and bortezomib | 84 (44.9) | 90 (45.2) |
Type of MM, n (%) | ||
  IgA | 50 (26.7) | 55 (27.6) |
  IgD | 10 (5.4) | 10 (5.0) |
  IgG | 107 (57.2) | 112 (56.3) |
  IgM | 1 (0.5) | 1 (0.5) |
  Missing | 19 (10.2) | 21 (10.6) |